Rare disease-focused Eiger BioPharmaceuticals Inc. reached a quick decision on its Phase II candidate in pulmonary arterial hypertension after ubenimex failed to show a benefit in the primary or secondary endpoints in a Phase II study. The firm revealed Jan. 16 that it will cease development in that indication, while continuing a Phase II study with the same molecule in lymphedema.
Eiger Shifts Focus After Phase II Failure In PAH
Finding no improvement with ubenimex in PAH, Eiger ends development but continues with the drug in lymphedema, plus hepatitis D and post-bariatric hypoglycemia candidates.
More from Clinical Trials
• By
Compass' bispecific antibody tovecimig hits primary efficacy endpoint in Phase II/III top-line data in advanced biliary tract cancer, and may have class side-effect advantages. But additional survival data may be needed to support US approval.
• By
BeiGene’s Phase III ociperlimab joins the list of failed TIGIT inhibitors, as candidates from Roche, Merck & Co. and others have failed late-stage studies.
• By
With new Phase II data, Edgewise asserted that EDG-7500, a sarcomere modulator, could offer better efficacy and safety than cardiac myosin inhibitors in hypertrophic cardiomyopathy.
• By
Investing heavily in antibody-drug conjugates, AbbVie is pioneering a dual STEAP1xPSMA-targeting approach in prostate cancer, as other candidates advance.
More from R&D
• By
Investing heavily in antibody-drug conjugates, AbbVie is pioneering a dual STEAP1xPSMA-targeting approach in prostate cancer, as other candidates advance.
• By
Strong sales growth for the German group’s SGLT2 inhibitor in 2024
• By
After a more than three-year hiatus, China's Hengrui has signalled its return to multiregional Phase III trials as it looks to globalize its innovative pipeline. Meanwhile, a number of other Chinese players have announced plans to kick off Phase III trials this year and beyond.